Riverview Trust Co Makes New Investment in DexCom, Inc. (NASDAQ:DXCM)

Riverview Trust Co purchased a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 231 shares of the medical device company’s stock, valued at approximately $32,000.

A number of other large investors also recently added to or reduced their stakes in DXCM. DSM Capital Partners LLC acquired a new stake in shares of DexCom in the fourth quarter valued at $28,000. Valley National Advisers Inc. increased its holdings in DexCom by 73.0% in the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after buying an additional 103 shares during the last quarter. MV Capital Management Inc. increased its holdings in DexCom by 99.3% in the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock valued at $34,000 after buying an additional 138 shares during the last quarter. Smithfield Trust Co increased its holdings in DexCom by 103.1% in the fourth quarter. Smithfield Trust Co now owns 325 shares of the medical device company’s stock valued at $40,000 after buying an additional 165 shares during the last quarter. Finally, Washington Trust Advisors Inc. increased its holdings in DexCom by 120.6% in the fourth quarter. Washington Trust Advisors Inc. now owns 353 shares of the medical device company’s stock valued at $44,000 after buying an additional 193 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at DexCom

In related news, EVP Sadie Stern sold 427 shares of the firm’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $115.05, for a total value of $49,126.35. Following the completion of the sale, the executive vice president now owns 75,877 shares in the company, valued at $8,729,648.85. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, EVP Michael Jon Brown sold 2,624 shares of DexCom stock in a transaction that occurred on Thursday, March 28th. The shares were sold at an average price of $140.04, for a total transaction of $367,464.96. Following the completion of the sale, the executive vice president now directly owns 68,682 shares in the company, valued at approximately $9,618,227.28. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Sadie Stern sold 427 shares of DexCom stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $115.05, for a total transaction of $49,126.35. Following the sale, the executive vice president now owns 75,877 shares of the company’s stock, valued at $8,729,648.85. The disclosure for this sale can be found here. Insiders sold a total of 57,700 shares of company stock worth $7,911,495 over the last 90 days. Company insiders own 0.30% of the company’s stock.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $110.31 on Wednesday. The company has a quick ratio of 2.53, a current ratio of 2.90 and a debt-to-equity ratio of 1.08. The company has a market cap of $43.87 billion, a P/E ratio of 71.17, a PEG ratio of 2.70 and a beta of 1.22. DexCom, Inc. has a 52 week low of $74.75 and a 52 week high of $142.00. The company has a 50-day moving average price of $124.29 and a 200 day moving average price of $125.85.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. The firm had revenue of $921.00 million during the quarter, compared to the consensus estimate of $911.20 million. DexCom had a net margin of 16.82% and a return on equity of 31.01%. Research analysts predict that DexCom, Inc. will post 1.78 earnings per share for the current year.

Wall Street Analyst Weigh In

DXCM has been the topic of several research reports. Raymond James raised their price objective on DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a report on Friday, April 26th. Citigroup raised their price objective on DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Canaccord Genuity Group raised their price objective on DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a report on Friday, April 26th. UBS Group raised their price objective on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. Finally, StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a report on Monday, June 10th. Four equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, DexCom has a consensus rating of “Moderate Buy” and an average price target of $140.94.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.